##common.pageHeaderLogo.altText##

Vol. 2 No. 6 (2022)

Formulation Development & Evaluation of Controlled Drug Delivery System: An Overview

Clinical Medicine And Health Research Journal, Vol. 2 No. 6 (2022), 22 November 2022 , Page 274-280
https://doi.org/10.18535/cmhrj.v2i6.117

Abstract

The therapeutic effect is brought about by the drug delivery system dispensing the active medicinal ingredient. Due to fluctuations in plasma drug levels, traditional drug delivery devices have poor bioavailability and cannot generate a continuous release. The drug must also be supplied at a tightly regulated rate and to the correct location for it to be most effective and safe. To solve the problems inherent in the current methods of administering medication, scientists are working on perfecting controlled drug delivery systems. Controlled pharmaceutical delivery systems have come a long way in the last twenty years, from bulk distribution to nanoscale precision to smart, patient-specific dosing. The paper's initial portion provides background knowledge on drug delivery methods, emphasizing pharmacokinetics. The article also discusses the pros and cons of more conventional drug delivery methods. Controlled drug delivery systems' design factors, categorizations, and schematics are also discussed in length. In addition, recent advances in nano-drug delivery, targeted, and innovative drug delivery utilizing stimuli-responsive, intelligent biomaterials are discussed. The limitations of regulated medicine distribution and some possible solutions are discussed at the end of the study.

Keywords:
  • : CDDS, Therapeutic Effects, DDS, Formulation development, Crispr Cas9, etc

How to Cite

Paul, S. ., Ahmed, T. ., Hasan, S. ., Rahman Bhuiyan, M. K. ., Kumar Das, S. ., & Symros, N. . (2022). Formulation Development & Evaluation of Controlled Drug Delivery System: An Overview. Clinical Medicine And Health Research Journal, 2(6), 274–280. https://doi.org/10.18535/cmhrj.v2i6.117

Download Citation

References

  • Panchagnula R. Transdermal delivery of drugs. Indian J Pharmacol. 1997;29:140–56.
  • Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Indian Pharm. 1998;24:327–36.
  • Rao PR, Diwan PV. Permeability studies of cellulose acetate free films for transdermal use: Influence of plasticizers. Pharm Acta Helv. 1997;72:47–51.
  • Thacharodi D, Rap KP. Development and in vitro evaluation of chitosan-based trandermal drug delivery system for the controlled delivery of propranolol hydrochloride. Biomaterials. 1995;16:145–8.
  • Krishna R, Pandit JK. Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J Pharm Pharmacol. 1996;48:367–70.
  • Bhat M, Shenoy DS, Udupa N, Srinivas CR. Optimization of delivery of betamethasone - dipropionate from skin preparation. Indian Drugs. 1995;32:211–4.
  • Darshana HD, Mangal NS, Sudhakar GD. Design and evaluation of an extended release tables of prochlorperazine maleate. Indian Drugs, 2000; 38: 69‐74.
  • Ravi kumar NMV, Pranita S, Dutta PK. Effect of swelling on chitosan‐amine oxide gel in extended release of drug. Indian Drugs, 1999; 36: 393‐98.
  • Jeganath. S, Asha. D, Sathesh Kumar. S, Keerthi S Nair, Senthil Kumaran. K. Oral Controlled Drug Delivery System – A Review. Research J. Pharm. and Tech, 2018; 11(2):797-804. doi: 10.5958/0974-360X.2018.00151.8.
  • Vyas SP, Khar RK. Controlled drug delivery: Concepts and Advances. 1st ed. Vallabh prakashan; 2002; 156-189.
  • Chien. YW. Novel drug delivery system. Volume 50.
  • Allen LV, Popvich GN, Ansel HC. Ansel’s Pharmaceutical dosage form and drug delivery system. 8th ed. 2004; 260-263.
  • Patrick JS. Martin’s Physical Pharmacy and Pharmaceutical Sciences. 3rd ed. Varghese Publishing House. Bombay: 1991; 512-519.
  • Kar RK, Mohapatra S, Barik BB. Design and characterization of controlled release matrix tablets of Zidovudin. Asian J Pharm Cli Res. 2009; 2:54-6
  • Lachaman L, Liberman HA, Kanig JL.The theory and practice of industrial pharmacy. 3rd ed. Bombay: Varghese publishing house 1987.
  • Jain NK. Controlled and novel drug delivery. CBS publisher and distribution. 1997; 1-25.
  • Venkataraman DSN, Chester A, Kliener L. An overview of controlled release system. Handbook of pharmaceutical controlled release technology. Marcel Dekker Inc. 2000; 1-30.
  • Modi Kushal, Modi Monali, Mishra Durgavati, Panchal Mittal, Sorathiya Umesh, Shelat Pragna. Oral controlled release drug delivery system: An overview. Int. Res. J. Pharm. 2013; 4(3):70-76.
  • Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics: Pharmacokinetics. 2nd ed. Vallabh Prakashan, Delhi: 2009; 399-401.
  • Hardenia A., Maheshwari N., Hardenia S.S., Dwivedi S.K., Maheshwari R., Tekade R.K. Basic Fundamentals of Drug Delivery. Elsevier; Amsterdam, The Netherlands: 2019. Scientific rationale for designing controlled drug delivery systems; pp. 1–28.
  • Fenton O.S., Olafson K.N., Pillai P.S., Mitchell M.J., Langer R. Advances in biomaterials for drug delivery. Adv. Mater. 2018;30:1705328. doi: 10.1002/adma.201705328.
  • Singh A.P., Biswas A., Shukla A., Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target. Ther. 2019;4:1–21. doi: 10.1038/s41392-019-0068-3.
  • Mitragotri S., Burke P.A., Langer R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat. Rev. Drug Discov. 2014;13:655–672. doi: 10.1038/nrd4363.
  • Bartucci R., Paramanandana A., Boersma Y.L., Olinga P., Salvati A. Comparative study of nanoparticle uptake and impact in murine lung, liver and kidney tissue slices. Nanotoxicology. 2020;14:847–865. doi: 10.1080/17435390.2020.1771785.
  • Lu L., Qi S., Chen Y., Luo H., Huang S., Yu X., Luo Q., Zhang Z. Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials. 2020;245:119987. doi: 10.1016/j.biomaterials.2020.119987.
  • Vallet-Regí M., Colilla M., Izquierdo-Barba I., Manzano M. Mesoporous silica nanoparticles for drug delivery: Current insights. Molecules. 2018;23:47. doi: 10.3390/molecules23010047.
  • Hassan S., Zhang Y.S. Chapter 10—Microfluidic technologies for local drug delivery. In: Santos H.A., Liu D., Zhang H., editors. Microfluidics for Pharmaceutical Applications. William Andrew Publishing; Amsterdam, The Netherlands: 2019. pp. 281–305.
  • Srivastava A., Yadav T., Sharma S., Nayak A., Kumari A.A., Mishra N. Polymers in drug delivery. J. Biosci. Med. 2015;4:69–84. doi: 10.4236/jbm.2016.41009.
  • Mogoşanu G.D., Grumezescu A.M., Bejenaru L.E., Bejenaru C. Chapter 8—Natural and synthetic polymers for drug delivery and targeting. In: Grumezescu A.M., editor. Nanobiomaterials in Drug Delivery. William Andrew Publishing; Amsterdam, The Netherlands: 2016. pp. 229–284.
  • Simutis K., Stonyte G., Mažutis L. Chapter 12—Antibody discovery using microfluidic systems. In: Santos H.A., Liu D., Zhang H., editors. Microfluidics for Pharmaceutical Applications. William Andrew Publishing; Amsterdam, The Netherlands: 2019. pp. 337–351.
  • Chen R., Sun Z., Chen D. Chapter 11—Droplet-based microfluidics for cell encapsulation and delivery. In: Santos H.A., Liu D., Zhang H., editors. Microfluidics for Pharmaceutical Applications. William Andrew Publishing; Amsterdam, The Netherlands: 2019. pp. 307–335.
  • Wei T., Cheng Q., Min Y.-L., Olson E.N., Siegwart D.J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 2020;11:3232. doi: 10.1038/s41467-020-17029-3.
  • Deng Y., Zhang X., Shen H., He Q., Wu Z., Liao W., Yuan M. Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases. Front. Bioeng. Biotechnol. 2020;7:489. doi: 10.3389/fbioe.2019.00489.
  • Subham Jain N., Preeti S., Amit B.P. Application of Quantum Dots in Drug Delivery. Nanosci. Nanotechnol. Asia. 2021;11:1–16. doi: 10.2174/2210681211666210211092823.
  • Natarajan J.V., Nugraha C., Ng X.W., Venkatraman S. Sustained-release from nanocarriers: A review. J. Control. Release. 2014;193:122–138. doi: 10.1016/j.jconrel.2014.05.029.
  • Beg S., Almalki W.H., Malik A., Farhan M., Aatif M., Alharbi K.S., Alruwaili N.K., Alrobaian M., Tarique M., Rahman M. 3D printing for drug delivery and biomedical applications. Drug Discov. Today. 2020;25:1668–1681. doi: 10.1016/j.drudis.2020.07.007.
  • Trenfield S.J., Awad A., Madla C.M., Hatton G.B., Firth J., Goyanes A., Gaisford S., Basit A.W. Shaping the future: Recent advances of 3D printing in drug delivery and healthcare. Expert Opin. Drug Deliv. 2019;16:1081–1094. doi: 10.1080/17425247.2019.1660318.
  • Chamundeeswari M., Jeslin J., Verma M.L. Nanocarriers for drug delivery applications. Environ. Chem. Lett. 2019;17:849–865. doi: 10.1007/s10311-018-00841-1.
  • Yadav K.S., Mishra D.K., Deshpande A., Pethe A.M. Chapter 7—Levels of Drug Targeting. In: Tekade R.K., editor. Basic Fundamentals of Drug Delivery. Academic Press; Cambridge, MA, USA: 2019. pp. 269–305.
  • Naz F., Siddique Y.H.J.C., Targets N.D.-D. Nanotechnology: Its application in treating neurodegenerative diseases. CNS Neurol. Disord. Drug Targets. 2021;20:34–53. doi: 10.2174/1871527319666200916121515.
  • Attia M.F., Anton N., Wallyn J., Omran Z., Vandamme T.F. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J. Pharm. Pharmacol. 2019;71:1185–1198. doi: 10.1111/jphp.13098.
  • Shah A., Aftab S., Nisar J., Ashiq M.N., Iftikhar F.J. Nanocarriers for targeted drug delivery. J. Drug Deliv. Sci. Technol. 2021;13:102426. doi: 10.1016/j.jddst.2021.102426.
  • Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021 Sep 29;26(19):5905. doi: 10.3390/molecules26195905.
    • Article Viewed: 0 Total Download

    ##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##

    Cover Image

    Information